Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com
Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

May 12th 2025

Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help drive improvements in personalized treatments for these patients.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

Digitally generated lungs held by doctor | Image credit: Image credit: PRASANNAPIX - stock.adobe.com
Chemo Plus IO Offers Survival Benefit in ES-SCLC vs Chemo Alone in Real-World Study

April 29th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

OS was the primary end point in the trial, and data from the planned interim analysis will be presented at an upcoming scientific meeting. | Image credit: Crystal light - stock.adobe.com
Tarlatamab Improves Overall Survival in Extensive-Stage SCLC

April 14th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

More News

JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC
October 14th 2022

JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
Immunotherapy graphic
October 9th 2022

Immunotherapy in SCC Still Marred by Challenges, Despite Efficacy in Some Patients

Jared Kaltwasser
Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).
HUDSON Trial Overview and Key Takeaways
October 7th 2022

HUDSON Trial Overview and Key Takeaways

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
Ticiana Leal, MD, Emory University School of Medicine
October 7th 2022

Dr Ticiana Leal: A Lot of Work Is Needed Regarding Early Detection in Lung Cancer

Laura Joszt, MA Skylar Jeremias
Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Person walking on a country road
October 6th 2022

NSCLC Differs Between Rural, Urban Patients in Key Ways

Jared Kaltwasser
Molecular differences may help explain geographic gaps in outcomes.
graphic of lung x ray
October 3rd 2022

Most Patients in China With Lung Cancer Experience Financial Toxicity

Jared Kaltwasser
A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.
Doctor preparing cancer treatments
October 1st 2022

Cemiplimab Shows Improved PFS, Comparable OS to Pembrolizumab in NSCLC

Jaime Rosenberg
In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials of the 2 PD-1/PD-L1 inhibitors in patients with advanced disease and PD-L1 ≥ 50%.
Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment
September 30th 2022

Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.
Ticiana Leal, MD, Emory University School of Medicine
September 29th 2022

Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient

Laura Joszt, MA Skylar Jeremias
Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
September 23rd 2022

Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer

Hayden E. Klein Maggie L. Shaw
During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
September 23rd 2022

Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Picture of cancer researchers
September 21st 2022

Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC

Jaime Rosenberg
With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Ticiana Leal, MD, Emory University School of Medicine
September 14th 2022

Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal

Laura Joszt, MA Skylar Jeremias
Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
lung cancer
September 12th 2022

Lung Cancer Screening Leads to Earlier Diagnosis, but Not Overdiagnosis

Jared Kaltwasser
A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
September 10th 2022

Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs

Maggie L. Shaw Hayden E. Klein
Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.
picture of patient consulting provider
September 8th 2022

Recommendations to Safeguard Quality Shared Decision-Making for Lung Cancer Screening

Allison Inserro
An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
August 29th 2022

Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC

Hayden E. Klein Maggie L. Shaw
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Colorful lung graphic
August 23rd 2022

Clinicians Slow to Adopt PD-1, PD-L1 Inhibitors in NSCLC

Jared Kaltwasser
A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.
Evaluating and Integrating New Data Into NSCLC Clinical Pathways
August 18th 2022

Evaluating and Integrating New Data Into NSCLC Clinical Pathways

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.
Immune Checkpoint Inhibitors in NSCLC Therapy
August 18th 2022

Immune Checkpoint Inhibitors in NSCLC Therapy

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.
Ticiana Leal, MD
August 17th 2022

HER2m NSCLC an “Exciting Area of Active Investigation,” Says Dr Ticiana Leal

Laura Joszt, MA
Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Trilaciclib Before Chemotherapy May Prevent Hematological Events—With Savings
August 16th 2022

Trilaciclib Before Chemotherapy May Prevent Hematological Events—With Savings

Mary Caffrey
Caregivers
August 15th 2022

Caregivers of Patients With Early-Stage Lung Cancer Face Anxiety, Moderate Burden

Jared Kaltwasser
Health care providers can help alleviate caregiver burdens by teaching coping strategies, the authors said.
Image of a telemedicine appointment
August 12th 2022

Targeted Outreach Efforts Meaningful for Patients With Lung Cancer

Jared Kaltwasser
Patients were more likely to accept intervention from a psychologist if they received regular questionnaires.
NSCLC Outcomes: Clinical and Non-Clinical Evidence
August 8th 2022

NSCLC Outcomes: Clinical and Non-Clinical Evidence

An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC.
Using Clinical Pathways to Treat NSCLC
August 8th 2022

Using Clinical Pathways to Treat NSCLC

Edward Arrowsmith, MD, describes the value of using clinical pathways in NSCLC therapy and how they are used at his institution, including their multiple sites of care.
Immunotherapy Plus Chemoradiation Improves NSCLC Outcomes
August 5th 2022

Immunotherapy Plus Chemoradiation Improves NSCLC Outcomes

Jared Kaltwasser
New real-world evidence on non–small cell lung cancer (NSCLC) aligns with the results of a 2017 clinical trial.
Image of a lung scan and a stethoscope
July 31st 2022

New Screening Recommendations Not Likely to Erase Lung Cancer Disparities

Jared Kaltwasser
More people are eligible for screening, but a new analysis suggests lung cancer disparities are due to more than eligibility status.
Color-coded image of DNA
July 25th 2022

KRAS Inhibition May Improve Efficacy of Immune Checkpoint Blockade in Lung Cancer

Jared Kaltwasser
The research may eventually help clinicians optimize therapy with immune checkpoint inhibitors.
Alexander Spira, MD
July 22nd 2022

In KRYSTAL-1, Adagrasib for NSCLC Has 43% Response Rate

Mary Caffrey
<12345678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo